Quantum Genomics announced the publication of a new scientific article reporting the efficacy of its second drug-candidate, QGC606, in an experimental model of heart failure in the Canadian Journal of Cardiology. This article, entitled “QGC606, a best-in-class orally active centrally acting aminopeptidase A inhibitor prodrug, for treating heart failure following myocardial infarction,” presents the results of a study conducted with QGC606 in mice following myocardial infarction, in collaboration with the INSERM team led by Catherine Llorens-Cortes at the Collège de France and the team at the Institut of Biology of Paris-Sorbonne University directed by Pr. Onnik Agbulut.

The article is available online on the journal's website (Articles in Press: Canadian Journal of Cardiology (onlinecjc.ca); DOI: 10.1016/j.cjca.2022.01.019). The data reported in this article demonstrate the effectiveness of oral treatment with QGC606 to improve cardiac function and reduce fibrosis, thus preventing the onset of heart failure after myocardial infarction, at a dose 6 times lower than the firibastat. Data shows the efficacy of QGC606 is also comparable to that of ramipril selected as a drug reference but unlike ramipril, QGC606, like firibastat, does not affect blood pressure levels in mice.